Close

Encouraging NP001 clinical trial results for MND

Reading Time: 3 minutes Promising results from a Phase II clinical trial for a drug called NP001 have been announced by the biopharmaceutical company Neuraltus. The trial, conducted in America, suggested that NP001 is safe, well tolerated and could be beneficial for MND. Following these encouraging results, Neuraltus plan to begin a larger, Phase III trial of NP001 in the second half…